Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 28, 2007. The document serves as a notification of transactions involving directors, specifically detailing changes in share interests for Mr. Andrew P. Witty.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only reported activity is the exercise of share options and subsequent sale of shares by a director.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports a transaction executed under the GlaxoWelcome UK International Share Option Scheme.
Important Facts for Investors
- Director Transaction: Mr. Andrew P. Witty exercised 7,352 share options on June 28, 2007.
- Share Sale: Mr. Witty sold 7,352 ordinary shares immediately following the exercise.
- Transaction Price: The shares were sold at GBP 13.05 per share.
- Regulatory Basis: The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(a).